



Cantourage company presentation



Europe's Leading

MEDICAL CANNABIS PLATFORM

Investment Highlights

One of the very few, pan-European medical cannabis companies

Continued profitable growth in highly regulated markets

Scalable, asset-light and (working) capital-efficient business model

Market leader in Germany, UK, & Poland – expansion in other European markets planned

Diversified product portfolio catering to current and future patient needs

Growing markets



European medical cannabis markets are growing rapidly


Medical cannabis verifiably improves the quality of life

- ↗ Over 150 million people suffer from sleep disorders
- ↗ Around 60 million people struggle with anxiety disorders
- ↗ More than 100 million people live with chronic pain



Imports of medical cannabis in Germany

(in tons)



Source: BfArM (2025)

Two core challenges



Two core challenges leading to market fragmentation and inefficiency

1 Shortage of consistent supply & innovative products in the European medical cannabis market

- ↗ Many excellent cannabis growers worldwide
- ↗ Growers do not have required licenses & permits to manufacture pharmaceuticals
- ↗ High investments in facilities & capabilities required to get necessary licenses

2 Lack of doctors & pharmacies limiting access for patients

- ↗ Despite growing evidence, many doctors & pharmacists still lack awareness and practical experience with medical cannabis, with the result that it's often neither prescribed nor dispensed
- ↗ Very challenging & time-consuming for patients to get suitable cannabis-based medicine
- ↗ Therapies often not covered by health insurance companies

Supply solution



Cantourage addresses these two core challenges with its unique operating model

01

Cantourage + growers



**Certify selected
growers
worldwide**

02

Cantourage



**Import raw
materials into
the EU & the UK**

03

Cantourage + partners



**Manufacture
pharmaceuticals**

04

Cantourage



**Distribute & sell
to pharmacies
or wholesalers**




**Cantourage platform enabling
growers to quickly & efficiently
supply the European medical
cannabis markets**

Access solution




Cantourage addresses these two core challenges with its unique operating model

How to get a prescription for medical cannabis?



How to find a pharmacy dispensing medical cannabis?



Access solution



Cantourage addresses these two core challenges with its unique operating model

Cantourage's telemedicine platforms in Germany & UK offering **safe & efficient** start of therapy



Online registration

Patients complete the medical questionnaire online and upload the required documents; once the documents have been reviewed, they can book an appointment.



Initial consultation

The first appointment can take place on-site or online. During the consultation, the doctor reviews the patient's medical record. Then the course of treatment is determined.



Prescription

The prescription is sent to the pharmacy selected by the patient.



Medicine

The medication is prepared at the pharmacy. It can be picked up on-site or delivered to the patient's home.



Cantourage's telemedicine
platforms provide
safe & efficient access for patients
to medical cannabis

Asset-light

OPERATING MODEL



Unique asset-light operating model enabling further profitable growth

| |  Growing |  Production |  Wholesale |  Tele-Medicine |  No. of groups | |
|---|--|---|--|--|--|--|
|  cantourage |  |  |  |  |  1 | Sourcing from selected growers around the world and direct connection to pharmacies & patients |
| Vertically integrated companies |  |  |  | |  3 - 5 | Own cultivation capacities: mostly large investments in 1-3 facilities with limited flexibility |
| Wholesale companies | | |  | |  20+ | Limited product range and low profit margins (Most German cannabis companies) |
| Providers of telemedicine | | | |  |  5 - 10 | Providers with patient access whose sole source of income is fees charged to physicians & patients for prescriptions |

Diverse portfolio

OF PRODUCTS




Successful in key market segments

Dried flowers



Cannabidiol API



Dronabinol API



Dronabinol Solution




Flower portfolio



Global network enables flexible responses to patient needs

- ↗ Multi-brand strategy enables a **broad offering** from “value” to “premium”
- ↗ **Revenue-sharing model** with growers
- ↗ Pharmacies and patients particularly appreciate the **wide range of products**




Current footprint

& FURTHER GROWTH



Innovative products, reliable quality control and regulatory expertise offer a strategic competitive advantage

**Cantourage mainly
operates in five
countries**



**and considers France,
Italy & Spain to be
promising markets
for future growth.**

Change expected

IN GERMANY



Expected changes to the legal framework as an opportunity for further market share gains

Proposed changes

- ↗ **From option for online-only prescription to at least one in-person interaction between doctor & patient per year**
- ↗ **From mail-order to pick-up in local pharmacies**

Expected timeline

| December 2025 | January 2026 | End of Q1 2026 | (?) 2026 |
|---------------|--------------|----------------|----------|
| • | • | • | • |

First reading in Bundestag Expert discussion Second & third reading in Bundestag Implementation

Reference case

- ↗ **Polish market fully recovered within 12-15 months after total ban of telemedicine**

The **flexible & agile** operating
model allows for swift reactions
to changing market demands
all over Europe


**Cantourage has diversified
its business right from the start**

**– with regard to products
& target markets**

Core KPIs



Flower sales (in g)




SKUs (#)

As of end of 2025

200+

↗ In 2025, Cantourage supplied flowers to ~100 000 patients on a monthly basis

Strong performance



Outlook

The European cannabis market is characterised by regulatory liberalisation and rising demand. As a publicly listed company, we are only just beginning to translate this momentum into sustainable growth.

Europe is expected to become the world's largest market for medical cannabis

The trend toward legalizing medical cannabis is gaining momentum

Demand is rising rapidly, driven by an aging population

Cantourage's continued product innovation fuels further market share gains

The opening of a recreational market would present considerable upside potential

Cantourage Group SE

Feurigstr. 54, 10827 Berlin

+49 (0)30 4701 350 – 50

www.cantourage.com

 cantourage

LEGAL DISCLAIMER

The information contained in this presentation is provided solely for informational purposes and does not constitute an offer to sell, a solicitation of an offer to buy, or an invitation to subscribe for securities of Cantourage Group SE (the “Company”). It does not replace individual investment advice.

This presentation contains certain forward-looking statements that are based on current assumptions and forecasts of the Company’s management. Such statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, the financial position, or the performance of the Company to differ materially from the assessments expressed herein. The Company assumes no obligation to update or revise such forward-looking statements to reflect future events or developments.

All information has been prepared with due care. However, no guarantee is given as to the accuracy, completeness, or timeliness of the information. Any liability claims relating to material or non-material damage caused by the use of the information are fundamentally excluded, unless caused by intent or gross negligence.

All contents of this presentation are subject to copyright. Reproduction or use without the consent of Cantourage is not permitted.